Abatacept is a recombinant fusion protein containing components of IgG and cytotoxic T-lymphocyte-associated antigen-4 that inhibit costimulatory signal from antigen presenting cells and prevent activation of T cells. Several clinical trials have demonstrated the excellent efficacy and safety of abatacept ...
THU0542 In Vitro Anti-Inflammatory Effects of Dexamethasone and Ctla4-Ig (ABATACEPT) Combined TreatmentBackground In rheumatoid arthritis (RA) the combination of glucocorticoids (GC) and the fusion protein CTLA4-Ig (abatacept) allows to obtain better clinical improvement than CTLA4-Ig monotherapy. ...
Regulatory T cells (Treg) play suppressive functions and are modulated by Abatacept (CTLA4-Ig). Limited data are available on CTLA4-Ig effect on Treg population in Rheumatoid Arthritis (RA). Objectives: The aim of the study was to analyze if STAT3/STAT5 expression in CD4+ T cells in periph...
The CTLA4-Ig fusion proteins abatacept and belatacept are clinically proven immunosuppressants used for rheumatoid arthritis and renal transplant, respectively. Given that both biologics are typically administered chronically by infusion, a need exists for a next-generation CTLA4-Ig with more convenient ...
Abatacept alleviates severe autoimmune symptoms in a patient carrying a de novo variant in CTLA-4. J Allergy Clin Immunol. 2016;137:327–30. Article PubMed Google Scholar Schwab C, et al. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects. J ...
In RA models, abatacept treatment leads to decreased activation of antibody-producing B cells [16]; additionally, the reduced release of proinflammatory cytokines, such as TNF-α and interleukin (IL)-1, IL-2, IL-4, IL-6 as well as interferon-gamma (INF-γ), and rheumatoid factor ...
CTLA4-Ig fusion protein molecule, abatacept, suitable for storage in the present pharmaceutical composition is produced by standard methods known in the art. For example, abatacept is prepared by recombinant expression of CTLA4 fused with CH2 and CH3 portion of human IgG in a mammalian host cell ...
Abatacept (Orencia®), is a CTLA4-Ig immunoadhesin consisting of the extracellular binding domain of CTLA4 linked to the Fc domain of a human IgG. Abatacept was developed to inhibit B7-mediated costimulation (Bluestone et al., 2006, Immunity 24:233-238), and is approved for the treatment ...
作者:Sarah E. Yost,Bruce Kaplan 出版社: John Wiley & Sons, Ltd 关键词:belatacept abatacept ITLA4‐Ig immunosuppression 出版时间: 2012/04/19 ISBN: 9781444355628 收藏 引用 批量引用 报错 分享 全部来源 求助全文 Wiley 来源图书 Immunotherapy in Transplantation 2012/04/19 站内活动 ...
CTLA4Ig (abatacept), a solu... JSJ Davis - 《Molecular Immunology》 被引量: 8发表: 2011年 ASP2409, A Next-Generation CTLA4-Ig, Versus Belatacept in Renal Allograft Survival in Cynomolgus Monkeys Belatacept is the first costimulatory blockade age Higashi,Y.,Daloze,... - 《American Journal ...